Innovative Bispecific Nanobody Therapy Targeting EGFR and MET for Cancer Treatment

VHH-P272 is a novel humanized nanobody-based bispecific antibody engineered to target both the epidermal growth factor receptor (EGFR) and the MET proto-oncogene, receptor tyrosine kinase (MET). Currently in the Biological Testing development stage, VHH-P272 is poised to address significant therapeutic needs in cancer treatment by simultaneously interfering with two critical signaling pathways implicated in tumor progression. The bispecific design, incorporating single-domain antibodies, offers the potential for enhanced tumor targeting and efficacy across diverse cancer types.

Licensing Opportunity

VHH-P272 is available for out-licensing, providing a unique opportunity for collaboration and co-development in the field of next-generation bispecific antibodies for oncology applications. Partners are invited to engage in advancing this innovative program toward clinical and commercial success.

Development Phase

Modality

VHH-P272 leverages a bispecific nanobody modality composed of two humanized single-domain antibodies—one directed against EGFR and the other against MET—fused to a human IgG1 Fc region featuring a knob-into-hole mutation. The nanobody architecture brings several advantages to cancer therapy, including compact molecular size for improved tumor penetration, high stability in physiological conditions, and the ability to access cryptic or sterically hindered epitopes. The bispecific format enables simultaneous engagement of EGFR and MET, which may contribute to overcoming resistance mechanisms and improving overall therapeutic effectiveness in oncology.

Target

EGFR and MET are critical receptor tyrosine kinases involved in cell proliferation, survival, and motility. EGFR is highly expressed on epithelial cells and is often overexpressed or mutated in a variety of solid tumors, contributing to uncontrolled growth and malignancy. MET, widely present in epithelial and mesenchymal tissues, is similarly implicated in cancer through its role in invasion, metastasis, and therapy resistance. Therapeutically targeting both EGFR and MET is a validated strategy to inhibit redundant or compensatory signaling in cancer pathways. VHH-P272's dual action on EGFR and MET enhances the potential for robust tumor growth inhibition and represents a strategically valuable approach in the competitive oncology landscape.

Mechanism of Action

VHH-P272 exerts its anti-cancer effects by simultaneously binding to EGFR and MET, thereby acting as a signal transduction modulator that interferes with critical pathways involved in tumor growth and survival. The anti-EGFR component blocks ligand-dependent activation and downstream proliferation signals, while the anti-MET component disrupts pathways mediated by hepatocyte growth factor stimulation, such as invasion and metastasis. This dual blockade is designed to address compensatory mechanisms that often lead to resistance in mono-targeted therapies. The nanobody-based bispecific format of VHH-P272 not only enables this synergistic signaling modulation but also offers a robust platform for further development as antibody–drug conjugates or next-generation bispecific constructs in the oncology pipeline.

Cancer

Cancer is a leading cause of morbidity and mortality worldwide, with an increasing incidence driven by population aging and lifestyle factors. Tumors develop through the accumulation of genetic and epigenetic alterations resulting in uncontrolled cell growth. Current mainstays of cancer therapy include surgery, chemotherapy, radiotherapy, immunotherapy, and targeted biological agents. However, significant limitations remain, such as drug resistance, adverse side effects, and limited options for certain tumor types. Targeted therapies against key pathways like EGFR and MET have shown efficacy, but their success is often limited by compensatory signaling networks and acquired resistance. Bispecific antibodies like VHH-P272 hold promise for enhancing therapeutic precision by blocking multiple pathways simultaneously, potentially overcoming resistance and improving outcomes in patients with cancers driven by EGFR and MET dysregulation.